Table 1

Baseline demographics and characteristics (FAS, N = 205)

Insulin icodec titration A (n = 51)Insulin icodec titration B (n = 51)Insulin icodec titration C (n = 52)IGlar U100 (n = 51)Total (N = 205)
Age, years59.8 (9.1)61.2 (8.0)61.4 (8.0)60.2 (8.1)60.7 (8.3)
Male, %52.954.953.852.953.7
Duration of type 2 diabetes, years9.8 (7.2)9.6 (4.9)9.2 (4.4)11.8 (6.8)10.1 (6.0)
Body weight, kg91.4 (17.6)90.4 (18.0)87.3 (14.0)86.4 (17.1)88.9 (16.7)
BMI, kg/m232.3 (4.8)31.4 (4.7)30.8 (3.8)30.6 (4.7)31.3 (4.5)
TIR, %57.0 (28.0)55.2 (26.3)51.0 (27.4)55.3 (29.2)54.6 (27.6)
FPG, mg/dL174 (33)180 (38)177 (41)168 (42)175 (39)
HbA1c, %8.0 (0.7)8.1 (0.8)8.2 (0.9)8.2 (0.8)8.1 (0.8)
HbA1c, mmol/mol63.9 (7.8)64.9 (8.4)65.6 (10.3)65.7 (9.1)65.0 (8.9)
Oral antidiabetic drug, n (%)*
 Metformin monotherapy20 (39.2)16 (31.4)25 (48.1)17 (33.3)78 (38.0)
 Metformin + SGLT2i12 (23.5)11 (21.6)11 (21.2)10 (19.6)44 (21.5)
 Metformin + DPP4i14 (27.5)19 (37.3)9 (17.3)16 (31.4)58 (28.3)
 Metformin + SGLT2i + DPP4i5 (9.8)5 (9.8)7 (13.5)8 (15.7)25 (12.2)
  • Data are means (SD) unless otherwise stated. Insulin icodec titration A: titration of insulin icodec to a prebreakfast SMBG target of 4.4–7.2 mmol/L (80–130 mg/dL) with dose adjustment of ±21 units. Insulin icodec titration B: titration of insulin icodec to a prebreakfast SMBG target of 4.4–7.2 mmol/L (80–130 mg/dL) with dose adjustment of ±28 units. Insulin icodec titration C: titration of insulin icodec to a prebreakfast SMBG target of 3.9–6.0 mmol/L (70–108 mg/dL) with dose adjustment of ±28 units. IGlar U100: titration of IGlar U100 to a prebreakfast SMBG target of 4.4–7.2 mmol/L (80–130 mg/dL) with dose adjustment of ±4 units.

  • * At screening.